Cutaneous Lupus Erythematodus Sjögren Systemic Sclerosis
Conditions
Interventions
None listed
Sponsors
reumatologie
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: lnclusion criteria for Sjögren's syndrome (SSj) patients are: diagnosis of primary SS according to the European American consensus group criteria, grade 3 or 4 Chisholm score in salivary gland biopsy and presence of antinuclear (ANA), anti-SSA and/or anti-SSB antibodies. Inclusion criteria for CLE patients are: diagnosis of subacute cutaneous lupus erythematosus (SCLE) or SLE with cutaneous lupus according to the Düsseldorf classification criteria . Presence of anti-nuclear (ANA), anti-SSA and/or anti-SSB antibodies. Active skin disease as assessed by the treating physician. lnclusion criteria for the SSc patients are: diagnosis of early diffuse cutaneous SSc, according to the VEDOSS criteria defined as having a diffuse skin involvement, presence of anti-nuclear antibodies (ANA) a disease duration (from fìrst non-ñaynaud symptom) of 10 points or > 25% in the past year. Patients will be selected with skin involvement of the legs, which allows the analysis of an inguinal lymph node as locoregional lymph node.
Exclusion criteria
Exclusion criteria: Exclusion criteria for both SSj patients and SSc patients are presence of active concurrent inflammatory or infectious condition, current or previous use of biologic treatment, previous other systemic autoimmune disease, diagnosis or positive serology for hepatitis C or Human lmmunodeficiëncy Virus.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine the difference in expansion, reactivity, function and regulation of autoreactive B and T cell clones compared to other B and T cell clones in inflammatory tissues of SSj versus CLE and SSc patients. | — |
Countries
Netherlands
Outcome results
None listed